TY - JOUR
T1 - Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia
AU - on behalf of the Japan Adult Leukemia Study Group
AU - Minamiguchi, Hitoshi
AU - Fujita, Hiroyuki
AU - Atsuta, Yoshiko
AU - Asou, Norio
AU - Sakura, Toru
AU - Ueda, Yasunori
AU - Sawa, Masashi
AU - Dobashi, Nobuaki
AU - Taniguchi, Yasuhiro
AU - Suzuki, Rikio
AU - Uchino, Yoshihito
AU - Tomita, Akihiro
AU - Tamaki, Shigehisa
AU - Hagihara, Maki
AU - Fujimaki, Katsumichi
AU - Yanada, Masamitsu
AU - Maeda, Yoshinobu
AU - Iwanaga, Masako
AU - Usui, Noriko
AU - Kobayashi, Yukio
AU - Ohtake, Shigeki
AU - Kiyoi, Hitoshi
AU - Matsumura, Itaru
AU - Miyazaki, Yasushi
AU - Naoe, Tomoki
AU - Takeshita, Akihiro
N1 - Funding Information:
The authors thank Yumi Satou, Yuka Komatsu, Ryoko Fujiyoshi, Shinya Satou, and Shuichi Miyawaki for their contribution on data management; Tomoya Maeda and Maho Ishikawa for data confirmation; Mio Kurata for her support of statistical analysis; and Gareth A. Roberts for English editing the manuscript. We thank all the patients and caregivers, the centers, and participating JALSG members for their support and commitment in this study. We wish to express our sincere gratitude to the late Katsuji Shinagawa for initiating this study as principal investigator.
Funding Information:
The trial was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan (Clinical Cancer Research Grant No. 23–004), the National Cancer Centre Research and Development Fund (Grant No. 23-A-23, 26-A-24), and the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED (17ck0106251). Acknowledgments
Funding Information:
Y.A. has received honoraria from Chugai Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Meiji Seika Pharma Co. Ltd., and Kyowa Hakko Kirin Co., Ltd. N.A. has received honoraria from SRL, Inc. and Nippon-Shinyaku Co., Ltd., and research funds from Chugai Pharmaceutical Co., Ltd. N.D. has received research funds from Fujimoto Pharmaceutical Co. and scholarship endowments from Pfizer Japan Inc. A.T. has received honoraria and research funds from Chugai Pharmaceutical Co., Ltd., and research funds from Kyowa Hakko Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Y.K. has received honoraria from Astellas Pharma Inc. H.K. has received honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K., and consulting fees from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., and Daiichi Sankyo Co., Ltd., and research funds from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., and Celgene Corporation. I.M. has received honoraria from Pfizer Japan Inc., research funds from Chugai Pharmaceutical Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. Y.M. has honoraria from Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. The other authors have no conflict of interest.
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/12
Y1 - 2020/12
N2 - Significant advancements have been achieved with regard to the outcomes of acute promyelocytic leukemia (APL) patients through the introduction of all-trans retinoic acid; however, early hemorrhagic death and differentiation syndrome remain the major causes of remission induction failure in patients with APL. To investigate early death, serious hemorrhage, and differentiation syndrome during remission induction therapy in terms of incidence, risk factors, influence on outcomes, and prophylactic effects of several new anticoagulants, the results of 344 patients enrolled in the Acute Promyelocytic Leukemia 204 study conducted by the Japan Adult Leukemia Study Group were analyzed. Early death was observed in 16 patients (4.7%), of whom 14 had serious hemorrhage and 2 had differentiation syndrome. Serious hemorrhage and differentiation syndrome of grade 2 or higher were observed in 21 and 54 patients, respectively. Patients who achieved complete remission had a 7-year disease-free survival of 84.8% if they did not experience serious hemorrhage and 40.0% if they experienced serious hemorrhage during remission induction therapy (P = 0.001). Risk factor analyses showed that higher white blood cell count was associated with early death, higher white blood cell count and lower platelet count with serious hemorrhage, and leukocytosis during induction therapy and higher body surface area with differentiation syndrome. In conclusion, these results indicate that patients with such high-risk features may benefit from more intensive supportive care. The hemorrhagic risk was not relieved by the introduction of new anticoagulants. Further studies are required to establish the predictive impact of body surface area on differentiation syndrome. This trial is registered with UMIN-CTR as C000000154 on September 13, 2005.
AB - Significant advancements have been achieved with regard to the outcomes of acute promyelocytic leukemia (APL) patients through the introduction of all-trans retinoic acid; however, early hemorrhagic death and differentiation syndrome remain the major causes of remission induction failure in patients with APL. To investigate early death, serious hemorrhage, and differentiation syndrome during remission induction therapy in terms of incidence, risk factors, influence on outcomes, and prophylactic effects of several new anticoagulants, the results of 344 patients enrolled in the Acute Promyelocytic Leukemia 204 study conducted by the Japan Adult Leukemia Study Group were analyzed. Early death was observed in 16 patients (4.7%), of whom 14 had serious hemorrhage and 2 had differentiation syndrome. Serious hemorrhage and differentiation syndrome of grade 2 or higher were observed in 21 and 54 patients, respectively. Patients who achieved complete remission had a 7-year disease-free survival of 84.8% if they did not experience serious hemorrhage and 40.0% if they experienced serious hemorrhage during remission induction therapy (P = 0.001). Risk factor analyses showed that higher white blood cell count was associated with early death, higher white blood cell count and lower platelet count with serious hemorrhage, and leukocytosis during induction therapy and higher body surface area with differentiation syndrome. In conclusion, these results indicate that patients with such high-risk features may benefit from more intensive supportive care. The hemorrhagic risk was not relieved by the introduction of new anticoagulants. Further studies are required to establish the predictive impact of body surface area on differentiation syndrome. This trial is registered with UMIN-CTR as C000000154 on September 13, 2005.
KW - Acute promyelocytic leukemia
KW - Body surface area
KW - Differentiation syndrome
KW - Disseminated intravascular coagulation
KW - Early death
KW - Serious hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85090086949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090086949&partnerID=8YFLogxK
U2 - 10.1007/s00277-020-04245-6
DO - 10.1007/s00277-020-04245-6
M3 - Article
C2 - 32879992
AN - SCOPUS:85090086949
VL - 99
SP - 2787
EP - 2800
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 12
ER -